SSA
BBOT

Schonfeld Strategic Advisors’s BridgeBio Oncology BBOT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.7K Buy
+11,504
New +$96K ﹤0.01% 2322
2024
Q4 		– Sell
-119,880
Closed -$1.25M – 2461
2024
Q3 		$1.25M Buy
+119,880
New +$1.24M 0.01% 1085

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Schonfeld Strategic Advisors's BBOT Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in BridgeBio Oncology (BBOT) in Q2 2026: 11,504 shares worth $87.7K. The stake represents ﹤0.01% of the portfolio and ranks #2322 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in BBOT as recently as Q3 2024.

Schonfeld Strategic Advisors first reported a position in BBOT in Q3 2024 and has held it in 2 quarters since. The position peaked at $1.25M in Q3 2024. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Schonfeld Strategic Advisors held 11,504 shares of BridgeBio Oncology worth $87.7K as of Q2 2026.
  • BridgeBio Oncology was a new Schonfeld Strategic Advisors position in Q2 2026.
  • BridgeBio Oncology made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2322 holding.
  • Schonfeld Strategic Advisors first reported a position in BridgeBio Oncology in Q3 2024 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's BridgeBio Oncology position peaked at $1.25M in Q3 2024.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.